摘要: fidence interval [CI], 0.16 to 0.54; P<0.001) and the annualized rate of relapse (0.10 vs. 0.36; hazard ratio, 0.26; 95% CI, 0.41; P<0.001). The mean disability score on a 10-point scale improved by 0.39 point in alemtuzumab group worsened 0.38 interferon beta-1a (P<0.001). In group, lesion burden (as seen T 2 -weighted magnetic resonance imaging) was reduced, as compared with that (P = 0.005). From month 12 36, brain volume 1 increased but decreased beta1a 0.02). Adverse events included autoimmunity (thyroid disorders [23% 3%] immune thrombocytopenic purpura [3% 1%]) infections (66% 47%). There were no significant differences outcomes between 12-mg dose 24-mg alemtuzumab. Conclusions patients early, relapsing–remitting multiple sclerosis, more effective than associated autoimmunity, most seriously manifesting purpura. study not powered identify uncommon adverse events. (ClinicalTrials.gov number, NCT00050778.)
colescambridge.org.uk
elsevier.com参考文章(27)
A. J. Coles, A. Cox, E. Page, J. Jones, S. A. Trip, J. Deans, S. Seaman, D. H. Miller, G. Hale, H. Waldmann, D. A. Compston, The window of therapeutic opportunity in multiple sclerosis : Evidence from monoclonal antibody therapy Journal of Neurology. ,vol. 253, pp. 98- 108 ,(2006) , 10.1007/S00415-005-0934-5
T. Moreau, N. Scolding, A. Compston, J. Thorpe, D. Miller, I. Moseley, G. Hale, H. Waldmann, D. Clayton, M. Wing, A. Compston, Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. The Lancet. ,vol. 344, pp. 298- 301 ,(1994) , 10.1016/S0140-6736(94)91339-0
Ludwig Kappos, Jack Antel, Giancarlo Comi, Xavier Montalban, Paul O'Connor, Chris H. Polman, Tomas Haas, Alexander A. Korn, Goeril Karlsson, Ernst W. Radue, Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis The New England Journal of Medicine. ,vol. 355, pp. 1124- 1140 ,(2006) , 10.1056/NEJMOA052643
Stuart J. Pocock, Richard Simon, Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial Biometrics. ,vol. 31, pp. 103- 115 ,(1975) , 10.2307/2529712
S.P. Cobbold, P.R.U.B. Rebello, H.Ff.S. Davies, P.J. Friend, M.R. Clark, A simple method for measuring patient anti-globulin responses against isotypic or idiotypic determinants. Journal of Immunological Methods. ,vol. 127, pp. 19- 24 ,(1990) , 10.1016/0022-1759(90)90335-S
K. P. Johnson, B. R. Brooks, J. A. Cohen, C. C. Ford, J. Goldstein, R. P. Lisak, L. W. Myers, H. S. Panitch, J. W. Rose, R. B. Schiffer, T. Vollmer, L. P. Weiner, J. S. Wolinsky, , Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial Neurology. ,vol. 45, pp. 1268- 1276 ,(1995) , 10.1212/WNL.45.7.1268
D. Y. Lin, L. J. Wei, I. Yang, Z. Ying, Semiparametric regression for the mean and rate functions of recurrent events Journal of The Royal Statistical Society Series B-statistical Methodology. ,vol. 62, pp. 711- 730 ,(2000) , 10.1111/1467-9868.00259
Andreas Laupacis, David L. Sackett, Robin S. Roberts, An assessment of clinically useful measures of the consequences of treatment. The New England Journal of Medicine. ,vol. 318, pp. 1728- 1733 ,(1988) , 10.1056/NEJM198806303182605
, D. S. Goodin, E. M. Frohman, G. P. Garmany, J. Halper, W. H. Likosky, F. D. Lublin, D. H. Silberberg, W. H. Stuart, S. van den Noort, Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. ,vol. 58, pp. 169- 178 ,(2002) , 10.1212/WNL.58.2.169
Otton, Turner, Frewin, Davies, Johnson, Autoimmune thrombocytopenia after treatment with Campath 1H in a patient with chronic lymphocytic leukaemia. British Journal of Haematology. ,vol. 106, pp. 261- 262 ,(1999) , 10.1046/J.1365-2141.1999.01576.X